EGF and cancer: Furthermore, new strategies has been developed this last decade to disturb ErbB receptor family dimerization and activation by targeting the transmembrane domain of these receptors: indeed, short synthetic peptides which mimick TM domains are able to inhibit specifically kinase activity and cell signaling induced by EGF and ErbB2 receptors in cancer cells (Bennasroune et al., 2004a).